AbbVie Lowers 2025 Earnings Forecast After USD 20 Billion Acquisition Spree Farhat Nasim5 April 2025 11:15 AM ISTAbbVie has been focusing on expanding its pipeline since its blockbuster arthritis drug, Humira, lost patent protection in 2023.
AbbVie to acquire Aliada Therapeutics for USD 1.4 billion in cash Ruchika Sharma2 Nov 2024 1:00 PM ISTNorth Chicago: AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology...
Shilpa Medicare arm gets Morocco registration nod for Adalimumab Ruchika Sharma25 July 2024 4:23 PM ISTHyderabad: Shilpa Medicare has announced that Shilpa Biologicals Pvt Ltd (SBPL), a wholly owned subsidiary of the Company has received registration...
Boehringer Ingelheim gets USFDA nod for high-concentration, citrate-free formulation of Cyltezo to treat multiple chronic inflammatory diseases Ruchika Sharma2 May 2024 11:30 AM ISTThe high-concentration formulation (100 mg/mL), which is now available as a pre-filled syringe or pre-filled autoinjector.
CVS Health to remove AbbVie rheumatoid arthritis drug Humira from some drug reimbursement lists in April Ruchika Sharma4 Jan 2024 12:30 PM ISTA CVS spokesperson said the company expects most of its customers to transition their coverage to biosimilars of Humira, known chemically as...
Biocon Biologics, Sandoz ink pact for distribution of immune disorder injection Adalimumab in Japan Ruchika Sharma23 Dec 2023 12:30 PM ISTAdalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira (generic name: adalimumab (genetical recombination)) and is indicated for...
Boehringer unveils 81 percent discounted biosimilar of AbbVie Humira Ruchika Sharma4 Oct 2023 3:30 PM ISTUntil recently, Humira was the world's biggest-selling prescription drug. It had sales of USD 21.2 billion in 2022.
Biocon Biologics's Hulio biosimilar to Humira, now available in US Ruchika Sharma4 July 2023 2:38 PM ISTHULIO is available at a list price (Wholesale Acquisition Cost) of 5% below the current Humira list price.
Coherus resolves part of dispute with AbbVie over Humira biosimilar Ruchika Sharma17 Jun 2023 11:00 AM ISTCoherus BioSciences said on Thursday it had agreed to retract a restraining order against AbbVie as the two fight over the terms of launching a...
U S government sets penalties on 43 drugs over price hikes Ruchika Sharma11 Jun 2023 2:30 PM ISTThe Medicare agency plans to send the first invoices to drugmakers in 2025 for the rebates owed to Medicare this year and for 2024.
AstraZeneca to leave leading US drug lobby group Ruchika Sharma17 May 2023 1:30 PM ISTAstraZeneca's exit follows those of AbbVie, maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs.
AbbVie trims profit forecasts on IPRnD expenses Ruchika Sharma7 April 2023 2:30 PM ISTUnited States: AbbVie Inc has lowered its full-year and first-quarter profit expectations, citing a $150 million hit from acquired in-process...
